UniQure gets an FDA decision date; Teva scraps brain drug study

Coverage, in order

1. 8d ago
   
   BioPharma Dive indie study

   UniQure gets an FDA decision date; Teva scraps brain drug study

   The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.